Response to Comments: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

This document (A60219) is a response-to-comments administrative notice regarding the MolDX LCD for hereditary transthyretin amyloidosis (DL39987/L39987). It records the comment period dates (2024-08-29 to 2024-10-12), notes that comments were received, and specifies the notice period (starting 2025-07-03) and effective date (2025-08-17); no clinical coverage criteria are included in this document and require review of the underlying LCD for coverage rules.

"Comment period for DL39987 (MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis LCD) ran from 2024-08-29 to 2024-10-12."

Sign up to see full coverage criteria, indications, and limitations.